This double-blind , placebo-controlled , multicenter study included 329 patients with poorly controlled diabetes randomized to once-daily treatment with 12.5 mg alogliptin ( n = 133 ) , 25 mg alogliptin ( n = 131 ) , or placebo ( n = 65 ) for 26 weeks .
